IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

​ Conditions: Recurrent Prostate Cancer; Prostate Cancer

Interventions: Drug: N-803; Drug: ETBX-71 Vaccine; Radiation: 18F-DCFPyL

Sponsors: National Cancer Institute (NCI)

Not yet recruiting Conditions: Recurrent Prostate Cancer; Prostate Cancer
Interventions: Drug: N-803; Drug: ETBX-71 Vaccine; Radiation: 18F-DCFPyL
Sponsors: National Cancer Institute (NCI)
Not yet recruiting